ColoNext®
Use
ColoNext is designed to identify inherited risks for colorectal and related cancers. Understanding gene mutations can help tailor monitoring strategies, influence treatment paths, and identify at-risk family members, providing a comprehensive picture of cancer predisposition based on personal or family history. This panel is useful for refining decisions on the frequency and initiation of screenings, prophylactic surgeries, treatment adjustments, and clinical trial eligibility. It is intended for patients with early-onset colorectal cancer, multiple primary cancers, significant family cancer history, or significant polyp accumulation.
Special Instructions
We offer family variant testing for blood relatives of patients with a pathogenic variant within 90 days of the original report. Testing emphasizes those closely related where possible. Service is limited to patients receiving care in U.S. or U.S. territories.
Limitations
Certain regions with pseudogene interference or insufficient coverage and quality thresholds are verified via Sanger sequencing. The MSH3 polyalanine repeat region is not analyzed. Specific gross deletions and duplications among ColoNext genes have detection restrictions based on methodological capabilities, such as targeted chromosomal microarray and MLPA confirmations, focusing primarily on clinically significant genetic alterations.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided